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Abstract Functional activity of N- and C-terminal £uorescent
fusion proteins between STAT6 and EGFP was demonstrated
through IL-4-dependent transcriptional activation and nuclear
translocation. The N-terminal (EGFP^STAT6) fusion protein
appeared to be more active than the C-terminal fusion. In
HEK-293 cells both fusion proteins formed £uorescent nuclear
foci following IL-4 stimulation, but in HeLa cells nuclear accu-
mulation was homogeneous. Stimulation of the NF-UB pathway
through TNFK treatment, or expression of p65^EGFP fusion
protein, repressed both basal STAT6-dependent transcriptional
activity and the extent of activation in response to IL-4. This
indicates a novel mechanism of inhibition of STAT6 signalling
by NF-UB activation.
2 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
STAT6, the signal transducer and activator of transcription
protein, is a critical component in one of two pathways that
mediate signalling from the interleukin 4 (IL-4) receptor [1].
Through STAT6, IL-4 regulates MHC class II, CD23 and IL-
4RK expression [2,3], B cell isotype switching [4], and T helper
cell di¡erentiation to the Th2 phenotype [5,6]. Thus, STAT6
plays a pivotal role in allergic conditions such as asthma,
rhinitis, and a variety of immune disorders such as type 1
diabetes, arthritis and enterocolitis.
On binding to its receptor, IL-4 activates the IL-4R-asso-
ciated janus kinases, JAK1 and JAK3. These tyrosine kinases
phosphorylate the receptor itself, generating a site to which
STAT6 can bind. The JAKs in turn phosphorylate STAT6
[7,8], allowing the STAT6 molecule to be released. The phos-
phorylated STAT6 molecules form dimers, which then trans-
locate to the nucleus and bind to GAS-like elements contain-
ing the consensus sequence TTCN4GAA. Other STAT’s rec-
ognise the similar consensus sequence TTCN3GAA, but not
N4 [9^11].
We have applied time-lapse £uorescence microscopy [12]
and novel GFP^STAT6 £uorescent fusion proteins to track
the dynamics of the movement of this transcription factor in
single living cells. Both N- and C-terminal fusions retained
STAT6 function as determined by protein translocation and
transcriptional activation. We also show for the ¢rst time that
activation of the tumour necrosis factor K (TNFK)/nuclear
factor UB (NF-UB) pathway inhibits the IL-4/STAT6 signal-
ling pathway.
2. Materials and methods
2.1. Materials
Human recombinant TNFK and human recombinant IL-4 were
from Calbiochem (UK), tissue culture medium was from Gibco Life
Technologies (UK) and foetal calf serum (FCS) from Harlan Seralab
(UK). Other chemicals were supplied by Sigma (UK).
2.2. Plasmids
The pC/EBP^STAT6luc reporter (obtained from Dr M. Varga and
Dr L. Severinsson, AstraZeneca R and D Lund, Sweden) contains
four GAS enhancer elements of the sequence TTCN4GAA, recognised
by STAT6, and additionally a C/EBP-binding site, all located up-
stream of the TATA box, controlling expression of ¢re£y luciferase
for production of the STAT6 reporter. All expression plasmids are
under the control of the human cytomegalovirus immediate early
(hCMV-IE) promoter. The construct pEGFP^STAT6, expressing an
N-terminal fusion-protein between human STAT6 and enhanced
green £uorescent protein (EGFP), was constructed by subcloning
the STAT6 cDNA sequence from pCRscript^STAT6 into pEGFP^
C2 (Clontech, UK). pCRscript^STAT6 was digested with NotI and
pEGFP^C2 with KpnI. The linearised vectors were blunt-ended with
T4 DNA polymerase and digested with EcoRI. This released a 2.6-kb
fragment (STAT6 cDNA), which was then ligated into the linearised
pEGFP^C2. The plasmid expressing a C-terminal fusion of STAT6 to
EGFP (pSTAT6^EGFP) was constructed by PCR-amplifying the
STAT6 sequence without the stop codon from pEGFP^STAT6 fol-
lowed by directional cloning into the EcoRI and KpnI sites of
pEGFP^N1 (Clontech). p65^EGFP was described previously [12].
2.3. Cell culture and transfection
HEK-293 (ECAAC No. 85120602) were grown in minimum essen-
tial medium (MEM) with Earle’s salts, 10% FCS, 1% non-essential
amino acids (NEAA) and 2 mM L-glutamate at 37‡C, 5% CO2. For
confocal microscopy, cells were plated onto 35-mm Mattek dishes
(Mattek, USA) at 1.6U105 cells in 2 ml of medium. HeLa cells
(ECACC No. 93021013) were grown in MEM with Earle’s salts,
plus 10% FCS, and 1% NEAA at 37‡C, 5% CO2. For confocal mi-
croscopy, cells were plated on 35-mm Mattek dishes at 4U104 cells in
2 ml medium. After 24 h, cells were transfected using Fugene 6
(Boehringer, Mannheim, Germany). The ratio of DNA:Fugene 6
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for all transfections was 1Wg DNA:2 Wl Fugene 6. For 24-well micro-
titre plate-based (Sarstedt, UK) luminescence assays from the pC/
EBP^STAT6 luciferase reporter plasmid, HEK-293 cells were seeded
at 3U104 cells per well and HeLa cells at 1U104 per well in 1 ml
medium/well. Cells were transfected 28 h later using Fugene 6 at
0.25Wg DNA plus 0.5Wl Fugene 6 per well. In transfections with
pEGFP^N1, pEGFP^STAT6 or pSTAT6^EGFP, the vectors were
diluted 1:10 with pC/EBP^STAT6 luciferase reporter (i.e. 0.1 Wg
EGFP vector with 0.9 Wg reporter). p65^EGFP plasmid was diluted
1:10 with EGFP^N1 prior to its subsequent 1:10 dilution with the
reporter. (This 1:100 dilution was required because higher concentra-
tions led to a high basal activation [12], with a resultant masking of a
TNFK-stimulated response.)
2.4. Reporter luminescence assays
Cells were plated in 24-well microtitre plates as described above.
Transfected cells were treated for 6 h prior to harvesting with 250 Wl
lysis bu¡er per well [13]. Each well was assayed in duplicate by trans-
ferring 100 Wl of lysate into white 96-well plates (Greiner, UK), and
ATP was added to a ¢nal concentration of 1.25 mM. Luminescence
was measured using a BMG Lumistar platereader ¢tted with an in-
jector (BMG Labtechnologies, UK), and 100 Wl of 1 mM luciferin
(Biosynth AG, Switzerland) was injected into each well. Experiments
were performed in triplicate.
2.5. Fluorescence microscopy
Confocal microscopy was carried out on transfected cells in Mattek
dishes in a Zeiss XL humidi¢ed CO2 incubator (at 37‡C, 5% CO2)
using a Zeiss LSM510 Axiovert microscope with a 40U phase con-
trast oil immersion objective (N.A. = 1.3) when visualising HeLa cells,
and a 63U objective (N.A.= 1.4) when visualising HEK-293 cells.
Excitation of EGFP was performed using an Argon ion laser at 488
nm. Emitted light was re£ected through a 505^550-nm bandpass ¢lter
from a 540-nm dichroic mirror. Data capture and extraction was
carried out with LSM510 version 3 software (Zeiss, Germany). For
the EGFP fusion proteins, mean £uorescence intensities were calcu-
lated for each time point for both nuclei and cytoplasm. Nuclear:cy-
toplasmic £uorescence intensity ratios were determined relative to the
initial ratio at t=0 min. For visualisation of the EGFP^STAT6 foci in
the nuclei of HEK-293 cells (Fig. 2C) a stack of 40 images of 3-Wm
slices with an interval of 0.2 Wm was deconvolved using a calculated
point spread function, and then rendered with the transparency func-
tion of LSM510 software.
3. Results
3.1. Characterisation of the functional activity of N- and
C-terminal EGFP^STAT6 fusion proteins in HEK-293
cells
To investigate the dynamics of STAT6 protein transloca-
tion, we constructed vectors expressing both C- and N- ter-
minal fusion proteins between STAT6 and EGFP. To charac-
terise the functional activity of the expressed proteins, an IL-4
dose^response curve was obtained from HEK293 cells trans-
fected with each STAT6 construct (or an EGFP^N1 control)
together with a STAT6 luciferase reporter construct (Fig. 1).
As previously reported [11], these data demonstrate that the
HEK-293 cells are STAT6 de¢cient, as no response to IL-4
was observed when the cells were transfected with EGFP^N1
alone. Both the N- and C-terminal fusion proteins were able
to mediate signi¢cant IL-4-dependent transcriptional activa-
tion of the reporter construct. However, the EC50 to IL-4
di¡ered signi¢cantly between the cells expressing the two fu-
sion proteins (EGFP^STAT6 20.98S 1.79 pg/ml; STAT6^
EGFP 12.87S 1.43 pg/ml) and the N-terminal EGFP^
STAT6 fusion protein had a higher e⁄cacy, with a 7.03 S
0.14 (P6 0.001)-fold induction of the STAT6 reporter com-
pared to a 5.23S 0.11-fold induction in cells overexpressing
the C-terminal STAT6^EGFP fusion protein.
3.2. Imaging of the dynamic localisation of EGFP^STAT6
£uorescent proteins in IL-4-stimulated HEK293 cells
The dynamics of protein localisation following IL-4 stimu-
lation were determined by confocal microscopy (Fig. 2). In
unstimulated HEK-293 cells, both £uorescent fusion proteins
were evenly distributed throughout the cells (Fig. 2A,D).
However, upon stimulation with IL-4 (10 ng/ml), both the
STAT6 fusion proteins were observed to form foci in the
nuclei. Typically, the number of foci increased over time
(Fig. 2D^F), stabilising in number at around 60^80 min,
with approximately 50 foci per nucleus (Fig. 2C). The forma-
tion of foci was evident in the majority of cells and occurred
with both £uorescent fusion proteins.
3.3. Characterisation of the function of the STAT6-£uorescent
fusion proteins in HeLa cells which express functional
endogenous STAT6
Given that the nuclear translocation of the STAT6 con-
structs in the HEK-293 cells was di⁄cult to quantify (due
to the uneven nuclear distribution and the dynamic three-di-
mensional movement of the foci), we also investigated the
activity of the fusion proteins in other cells. Signi¢cant homo-
geneous nuclear translocation of both fusion proteins was
observed in HeLa cells in response to IL-4 (Fig. 2G^J). Con-
trol transfections with EGFP^N1 revealed no nuclear trans-
location in response to IL-4 (data not shown).
Unlike HEK-293 cells, HeLa cells express functional levels
of endogenous STAT6. We therefore compared the IL-4 re-
sponses of GFP-expressing (control) cells with those express-
ing the seemingly more active N-terminal EGFP^STAT6 fu-
sion protein. A dose^response curve to IL-4 (Fig. 3) obtained
from cells transfected with the empty expression vector
EGFP^N1 revealed an EC50 of 73.02 S 2.63 pg/ml, and a max-
imal-fold induction of the STAT6 luciferase reporter of
3.58S 0.08. In contrast, when EGFP^STAT6 was overex-
pressed there was an approximate six-fold increase in the re-
sponse to IL-4-induced transcription, with an EC50 of
11.40S 2.85, and an accompanying augmentation in transcrip-
tional activity to 4.82S 0.17-fold induction of the STAT6 re-
porter.
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Fig. 1. Dose^response curves for IL-4 in HEK-293 cells expressing
STAT6 £uorescent fusion proteins. HEK-293 cells were co-trans-
fected with a C/EBP^STAT6 luciferase reporter, and either the
EGFP^N1 control EGFP expression vector, the N- (EGFP^STAT6)
or C-terminal (STAT6^EGFP) fusion protein expression vectors.
Cells were stimulated with IL-4 24 h following transfection, and as-
sayed 18 h later. (*P6 0.01, Student’s t-test). Each data point repre-
sents mean valuesS S.E.M. from triplicate experiments.
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Fig. 2. Nuclear translocation of STAT6 £uorescent fusion proteins in HEK-293 and HeLa cells in response to stimulation with 10 ng/ml IL-4.
A^C: HEK-293 cells expressing N- terminal EGFP^STAT6. A: Single confocal image before stimulation with IL-4. B: 80 min after stimulation
with IL-4. C: Assembled stack of confocal slices showing typical numbers of nuclear £uorescent foci 80 min after IL-4 stimulation. D^F: Con-
focal images of HEK 293 cells expressing C-terminal STAT6^EGFP before stimulation (D), 40 min after stimulation (E) and 80 min after stim-
ulation with 10 ng/ml IL-4 (F). G^J: HeLa cells expressing N-terminal EGFP^STAT6 (G,H) or C-terminal STAT6^EGFP (I,J) before (G,I)
and 80 min after (H,J) stimulation with IL-4.
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Fig. 3. Dose^response to IL-4 in HeLa cells expressing the EGFP^
STAT6 fusion protein. HeLa cells were co-transfected with a
C/EBP^STAT6 luciferase reporter, and either the EGFP expression
vector, or the N-terminal EGFP^STAT6 expression vector. Cells
were stimulated with IL-4 24 h following transfection, and assayed
18 h later. (*P6 0.01, Student’s t-test). Each data point represents
mean values S S.E.M. from triplicate experiments.
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Fig. 4. Rate of nuclear translocation of STAT6 £uorescent fusion
proteins in HeLa cells following IL-4 stimulation. HeLa cells ex-
pressing either N-terminal EGFP^STAT6 or C-terminal STAT6^
EGFP were stimulated with 10 ng/ml IL-4 and imaged by confocal
microscopy over an 80 min period. The images were analysed to es-
tablish the nuclear:cytoplasmic ratio and its relative change follow-
ing stimulation is shown. These data represent the mean of three ex-
periments (v 4 cells per experiment). P6 0.05 (Student’s t-test)
when comparing 60 min time-point to start for each fusion protein.
Bars represent S.E.M.
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The extent and timing of translocation in HeLa cells in
response to IL-4 was determined. The degree of translocation
(at 60 min following stimulation with 10 ng/ml IL-4) was
similar for cells expressing both fusion proteins, with a
1.73S 0.07-fold increase in the nuclear:cytoplasmic ratio of
the N-terminal fusion compared to 1.77S 0.05 for the C-ter-
minal fusion (Fig. 4). When comparing the mean of cells
taken at 2 min and 60 min following stimulation with IL-4,
in both instances the degree of translocation was signi¢cant
(N-terminal EGFP^STAT6, 2 min vs 60 min, P6 0.001;
C-terminal STAT6^EGFP, P6 0.05). Of the two fusions the
N-terminal fusion protein appeared to respond slightly faster
following stimulation with IL-4 (10 ng/ml) than the C-termi-
nal fusion, though both constructs reached maximal translo-
cation at approximately the same time.
3.4. p65/NF-UB inhibits the STAT6 signalling pathway
We investigated the e¡ect of the NF-UB signalling pathway
on N-terminal EGFP^STAT6 fusion protein-mediated signal-
ling by IL-4 (Fig. 5). The transcriptional activity of the
STAT6 reporter was measured in HEK-293 cells overexpress-
ing EGFP^STAT6 and a control EGFP expression vector.
Treatment of cells with 100 pg/ml TNFK decreased the tran-
scriptional activity of the STAT6 reporter compared to un-
treated cells. The activity of the STAT6 reporter following
IL-4 treatment alone resulted in a 4.18S 0.07-fold induction
of the STAT6 reporter. This was signi¢cantly inhibited (to
2.1S 0.01-fold induction, P6 0.05) by pre-treatment of cells
with 100 pg/ml TNFK 20 min prior to treatment with 10 pg/
ml IL-4.
In order to investigate whether this e¡ect was NF-UB-medi-
ated, we co-transfected a functional p65^EGFP expressing
vector [12], together with EGFP^STAT6, into HEK-293 cells.
The expression of p65^EGFP signi¢cantly decreased the basal
activity of the STAT6 reporter 1.9-fold (P=0.014, n=3) com-
pared to expression of EGFP control (data not shown). Treat-
ment with TNFK alone slightly repressed basal STAT6 report-
er activity under the conditions of overexpressed p65 and
STAT6 (Fig. 5). In agreement with the TNFK-treated cells
without p65^EGFP, we saw signi¢cant inhibition of the
IL-4-induced reporter activity in cells overexpressing p65,
with IL-4 stimulating a 1.81 S 0.03-fold induction over basal
conditions. No signi¢cant further attenuation of the IL-4 re-
sponse was observed in p65 overexpressing cells pre-treated
with TNFK, perhaps re£ecting that p65 expression already
gave maximal NF-UB stimulation (and hence STAT6 inhibi-
tion) [12].
4. Discussion
The aim of this study was to quantitatively track the regu-
lation of IL-4-mediated gene expression. Expression of both
N- and C-terminal STAT6-£uorescent fusion proteins demon-
strated their functional activity through IL-4-dependent tran-
scriptional activity and nuclear translocation. There was a
signi¢cant di¡erence between the EC50s for IL-4 (as deter-
mined from transcriptional activity) for the two fusion pro-
teins. The N-terminal EGFP^STAT6 also conferred a higher
stimulation by IL-4 compared to the C-terminal STAT6^
EGFP. The highly conserved N-terminal of STAT6 has
been shown to be responsible for oligomerisation [14], so fa-
cilitating co-operative DNA binding on promoters containing
multiple potential STAT recognition sites. The more critical
domains, for STAT6 activation through dimerisation (SH2
domain) and transcriptional activation, are located at the
C-terminal end. The C-terminally located EGFP could there-
fore be encumbering receptor docking and/or phosphorylated
STAT6 dimerisation either through an e¡ect on the SH2 do-
main, or alternatively through damping of transcription acti-
vation. The C-terminal EGFP did not signi¢cantly a¡ect the
extent of nuclear translocation of the fusion protein in HeLa
cells, perhaps supporting the conclusion that the inhibitory
a¡ects on transcriptional activation may not be via inhibition
of docking and dimerisation. Thus, an e¡ect of the C-terminal
fusion on the activation of transcription seems more likely,
particularly since the transcription activation domain has the
closer proximity to the EGFP.
In HEK-293 cells, IL-4-stimulated £uorescent protein foci
formation in the nucleus. This phenomenon was previously
demonstrated by immunocytochemistry in bovine aortic endo-
thelial cells, and was also seen to occur with activated STAT1
[15]. One possible explanation is that these foci represent
stores for excess transcription factor. The fact that the nuclear
foci can occur in certain cell types with either native STAT6
protein or exogenous £uorescent STAT6 protein expression
suggests that they may have a functional signi¢cance.
When studying the transcriptional activity of the EGFP^
STAT6 in HeLa cells, it was observed that expression of the
fusion protein resulted in a signi¢cant shift in both EC50 and
e⁄cacy compared to that obtained with untransfected cells.
This di¡erence in EC50 might be explained by overexpression
of STAT6, resulting in a basal activity su⁄cient to drive the
synthesis of new IL-4 receptors [16]. This might increase the
number of receptors per cell so that lower doses of IL-4 could
signal transcriptional activation. The increase in maximal
transcriptional induction through STAT6-expression could
occur if the normal signalling pathway did not require acti-
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Fig. 5. The e¡ect of NF-UB activation on STAT6 signalling. HEK-
293 cells were transfected with pC/EBP-STAT6 luciferase reporter
together with pEGFP^STAT6 and pEGFP^N1 (darker bars), or
pEGFP^STAT6 and p65^EGFP (clear bars). The cells were treated
with 100 pg/ml TNFK and/or 10 ng/ml IL-4, with TNFK treatments
(or a control) being performed 20 min prior to stimulation with
IL-4 (*P6 0.05 (5% LSD) cf. IL-4 stimulation in pEGFP^N1 ex-
pressing cells). Each data point represents mean values SS.E.M.
from triplicate experiments.
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vation of all DNA-binding sites to achieve the required IL-4
response. This leaves the potential for additional activation to
occur during cellular events that require enhancement of the
IL-4 signalling pathway [17^19]. Increased expression of
STAT6 might utilise this extra capacity for activation of tran-
scription.
There is considerable evidence for the interaction of STAT6
and the p50 NF-UB subunit when their respective pathways
are activated [18,20^22]. Our results indicate a previously un-
reported functional interaction between the p65 and STAT6
transcription factors. Pre-stimulation of HEK-293 cells with
TNFK attenuated IL-4-induced transcription of the STAT6
luciferase reporter. This observation was supported by the
fact that in the absence of IL-4 stimulation TNFK reduced
basal transcription in the presence of overexpressed STAT6.
This suggests a speci¢c action of the TNFK pathway on
STAT6. Expression of the p65 subunit, which is the most
common partner to p50 in the activated form of NF-UB
[23], signi¢cantly inhibited IL-4-induced transcription. Pre-
treatment with TNFK was unable to further attenuate the
IL-4 response, most likely because the overexpression of p65
saturated the TNF-signalling pathway [12].
It has previously been suggested that the NF-UB subunits
p65 and p50 could interact with STAT6 in vitro [18]. How-
ever, in vivo only p50 could be co-immunopreciptated with
STAT6 in nuclear extracts of cells stimulated with IL-4 [17].
Our observation of an inhibitory e¡ect by the TNFK/p65NF-
UB pathway on IL-4 signalling is previously unreported. Most
studies have focused on the in£uence of the IL-4 pathway on
the TNFK/NF-UB pathway. These studies suggest that IL-4,
through STAT6, inhibits TNFK-stimulated transcription
[20,22,24,25]. Those studies in which the TNFK activation
was assessed through promoter activity were performed used
natural promoters [17] which contained multiple di¡erent
transcription factor binding sites. Our study has utilised a
synthetic STAT6 promoter and therefore indicates that the
inhibitory action of p65 on the IL-4-induced STAT6 reporter
activity is likely to be through a direct functional interaction
with STAT6.
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